Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch table for April 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during April 2014.

For an indepth analysis of these deals, read 'Pharma deals during April 2014'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

GSK/ Novartis
Acquisition
Oncology portfolio including pipeline products
15,500
Biomet/ Zimmer Holdings
Acquisition
Devices - Musculoskeletal/ Orthopaedics
13,350
Novartis/ GSK
AcquisitionVaccines portfolio, excluding influenza business
7,100
Questcor/ Mallinckrodt
AcquisitionActhar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions
5,600
Novartis/ Eli Lilly
AcquisitionAnimal Health franchise
5,400
Ranbaxy Laboratories/ Sun Pharmaceuticals
AcquisitionGenerics including Lipitor, Nexium, Diovan
3,200
Furiex/ Forest Labs
AcquisitionIBS, eluxadoline, a mu opioid receptor agonist/ delta opioid receptor antagonist for treating symptoms of IBD (NDA-ready)
1,460
Insight Pharmaceuticals/ Prestige Brands
AcquisitionOTC - 30 brands Women's Health and personal care products, including pregnancy testing; MONISTAT® vaginal anti-fungal
750
iPerian/ BMS
Acquisition
CNS/ Tauopathies, mAB IPN007 to treat progressive supranuclear palsy (PSP) (preclinical)
725
Forma Therapeutics/ Celgene
R&D collaboration + options: to extend, license, acquire company  3.5-year drug discovery collaboration covering a broad range of protein target families
600
Andromeda Biotech/ Hyperion Therapeutics
AcquisitionDiaPep277 24-amino acid peptide derived from human heat shock protein 60 (hsp60) to treat T1DM (p3)
570
Oryzon/ Roche (pRED)
Early stage drug research pact
Oncology - LSD1 inhibitors, Orphan cancer blocker ORY-1001 (p1/2a for acute myeloid leukaemia)
521+
Iquum/ Roche
AcquisitionMolecular Diagnostics - Laboratory-in-a-tube (Liat™) System
450
AccessClosure/ Cardinal Health
Acquisition

Devices - Mynx vascular closure device

320
GSK/ Amgen
Termination
Prolia (denosumab) for osteoporosis in certain countries *
275
Sentinal Oncology/ Oncothyreon
Collaboration
Preclinical checkpoint kinase 1 (Chk1) programme
174
Aptiv Solutions/ ICON
AcquisitionCRO/ Adaptive Clinical Trials
143.5
California Stem Cell/ NeoStem
Acquisition
Stem cell immune-based therapy Melapuldencel-T, to treat metastatic melanoma (p2)
124+
New Wave Surgical/ CovidienAcquisition
Device - D-HELP kit (to be re-named Clearify Visualization System)
100+
Agenus/ Merck & CoDiscovery collaboration/ licence

Immune checkpoint antibodies; 4-Antibody Retrocyte Display(R) platform100

Silom Medical Company/ ActavisAcquisitionGenerics - 25 products in various dosage forms
100

All deals are worldwide unless otherwise noted.

* Amgen will assume full marketing duties in areas including the EU, Switzerland, Norway, Russia and Mexico.  GSK retains rights in Australia (bone) and countries such as China, Brazil, India and South Korea for other uses.

The Deal Watch table is compiled by Medius Associates

20th May 2014

The Deal Watch table is compiled by Medius Associates

20th May 2014

From: Research, Sales

Share

Tags


Career advice

No results were found

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Infographics